Article

Segment 7 - Cost Considerations

Dr Peskin begins by stating, costs are exceedingly consequential. Cancer care and treatment is occupying, and with demographics being what they are, increasingly larger relative total cost of care across the US, including various national organizations.

Dr Peskin begins by stating, “costs are exceedingly consequential. Cancer care and treatment is occupying, and with demographics being what they are, increasingly larger relative total cost of care across the US,” including various national organizations.

He says insurers are working to address cost expenditures across departments as well as with surgical, medical, and radiology oncology partners. They are also including social workers and other care coordinators in that effort.

Some of the other factors payers are looking at include payment models such as bundled payments and areas of supportive care. Additionally, they are considering how to addresses the cost-effectiveness of advanced illness, compassionate care, and how to deal with patients through palliative care appropriately.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
David Awad, PharmD, BCOP
Coral Omene, MD, PhD, sitting for a vieo interview
Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center
Coral Omene, MD, PhD, sitting for a vieo interview
David Awad, PharmD, BCOP
Screenshot of Coral Omene, MD, PhD
H. John Beardsley, MBA, and Fauzea Hussain, MPH, sitting for a video interview
Adam Colborn, JD, associate vice president for congressional affairs, Academy of Managed Care Pharmacy (AMCP)
ASCO 2025
H. John Beardsley, MBA, and Fauzea Hussain, MPH, sitting for a video interview
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo